MorphoSys Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
MorphoSys Stock Forecast and Price Target
MorphoSys has an average price target of 68.00€ recently offered by three notable experts for 2024, which would represent a potential upside of approximately 0.44% from the last closing price in April, 2024 if reached. This potential increase is based on a high estimate of 68.00€ and a low estimate of 31.00€. If you're looking for information on MorphoSys stock, consider checking out the forecasts for comparable firms such as NYSE:BMY.
0.44% Upside
MorphoSys Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, MorphoSys's Price has fallen from 44.55€ to 0.00€ – a 100.00% decrease. In the next year, analysts predict that Fair Value will reach 71.37€ – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF84.52 | Buy/Sell | CHF105.00 | 24.59% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF220.00 | Buy/Sell | CHF307.83 | 23.86% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.30 | Buy/Sell | $58.15 | 13.87% |
| ARGX Stock Forecast | argenx | Outperform |
4
|
342.00€ | Buy/Sell | 531.81€ | 28.36% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$52.82 | Buy/Sell | $77.05 | 46.16% |
MorphoSys Revenue Forecast for 2023 - 2025 - 2030
In the last two years, MorphoSys's Revenue has fallen from 327.70€M to 278.27€M – a 15.08% decrease. According to 10 analysts, MorphoSys's Revenue will fall by 4.24% in the next year, reaching 266.48€M. For the next seven years, the forecast is for Revenue to grow by 157.24%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| REC Stock Forecast | Recordati Industria Chimica e ... | Hold |
18
|
49.74€ | Buy/Sell | 48.61€ | 1.93% |
| ZEAL Stock Forecast | Zealand Pharma A/S | Outperform |
8
|
kr598.00 | Buy/Sell | kr357.00 | 36.29% |
| ORNBV Stock Forecast | Orion Oyj | Hold |
14
|
32.27€ | Buy/Sell | 42.52€ | 30.15% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£17.89 | Buy/Sell | £28.11 | 65.34% |
| ALK B Stock Forecast | ALK-Abelló A/S | Outperform |
13
|
kr125.60 | Buy/Sell | kr109.25 | 5.89% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£15.24 | Buy/Sell | £28.89 | 106.69% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALM Stock Forecast | Almirall | Outperform |
16
|
8.18€ | Buy/Sell | 11.39€ | 40.59% |
| XNCR Stock Forecast | Xencor | Outperform |
6
|
$18.95 | Buy/Sell | $37.91 | 79.42% |
| COPN Stock Forecast | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF71.20 | Buy/Sell | CHF76.55 | 32.12% |
MorphoSys EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, MorphoSys's EBITDA has decreased from 38.69€M to -205.93€M – a 632.26% drop. For the following year, the 6 analysts predict that MorphoSys's EBITDA will drop by 5.12%, reaching -195.39€M. For the next seven years, the forecast is for EBITDA to grow by 186.98%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FAE Stock Forecast | Faes Farma | Hold |
18
|
3.18€ | Buy/Sell | 3.90€ | 14.78% |
| PHM Stock Forecast | Pharma Mar | Outperform |
13
|
26.62€ | Buy/Sell | 50.20€ | 80.32% |
| BSLN Stock Forecast | Basilea Pharmaceutica | Outperform |
6
|
CHF41.95 | Buy/Sell | CHF65.63 | 57.33% |
MorphoSys EBIT Forecast for 2023 - 2025 - 2030
MorphoSys's EBIT has decreased by 725.19% In the last two years, from 33.98€M to -212.44€M. In the following year, the 9 analysts surveyed believe that MorphoSys's EBIT will decrease by 10.86%, reaching -189.36€M. According to professionals, by 2030, MorphoSys's EBIT will have decreased by 41.57%, falling down to -124.14€M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DBV Stock Forecast | DBV Technologies | Outperform |
5
|
1.25€ | Buy/Sell | 4.07€ | 220.00% |
| KPTI Stock Forecast | Karyopharm Therapeutics | Outperform |
6
|
$1.28 | Buy/Sell | $6.00 | 290.63% |
| MOLN Stock Forecast | Molecular Partners | Outperform |
4
|
CHF3.35 | Buy/Sell | CHF9.50 | 179.10% |
MorphoSys EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, MorphoSys's EPS has fallen from 2.97€ to 0.00€ – a 100.00% decrease. In the next year, analysts predict that EPS will reach -5.52€ – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
.jpg)